COMMUNIQUÉS West-GlobeNewswire

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
03/06/2024
92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen) Majority of fully dosed [...]
RadNet, Inc. to Present at the Jefferies 2024 Global Healthcare Conference on June 5, 2024
03/06/2024
LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
03/06/2024
LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
03/06/2024
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today [...]
Orion is developing the Finnish life science industry in a unique collaboration project
03/06/2024
ORION CORPORATION PRESS RELEASE 03 June 2024 at 09.30 EEST Orion is developing the Finnish life science industry in a unique collaboration project Orion is participating in a project led by the University of Turku for [...]
RAMSAY SANTE : Agreement reached with the government on funding of private hospitals
03/06/2024
PRESS RELEASE Paris, 3 June 2024 Agreement reached with the government on funding of private hospitals After two months of mass mobilisation and intense discussions with the government, a compromise was reached on 24 [...]
RAMSAY SANTE : accord trouvé avec le gouvernement sur le financement de l'hospitalisation privée
03/06/2024
COMMUNIQUÉ DE PRESSE Paris, le 3 juin 2024 Accord trouvé avec le gouvernement sur le financement de l’hospitalisation privée Après deux mois de mobilisation massive et d'intenses discussions avec le gouvernement, un [...]
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care
03/06/2024
U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour [...]
Pharming Group to participate in June investor conferences
03/06/2024
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month [...]
Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates
03/06/2024
London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer [...]
Number of voting rights as of May 31, 2024
03/06/2024
Nicox SA Société anonyme with a registered capital of € 502,996.94 Head Office: Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois – 06410 Biot R.C.S. ANTIBES 403.942.642 On June 3 rd , 2024, MONTHLY [...]
Nombre de droits de vote au 31 mai 2024
03/06/2024
Nicox SA Société anonyme au capital de 502 996,94 euros Siège social : Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois, 06410 Biot R.C.S. ANTIBES 403.942.642 Le 03 juin 2024, PUBLICATION MENSUELLE DU [...]
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
03/06/2024
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share plan PARIS, FRANCE, 3 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services [...]
Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés
03/06/2024
Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés et son nouveau plan d’actionnariat salarié PARIS, FRANCE, 3 juin 2024 - Ipsen (Euronext: IPN; ADR: [...]
New data with daridorexant to be presented at SLEEP 2024
03/06/2024
Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with insomnia, will be presented at [...]
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
03/06/2024
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK presented new data from [...]
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
03/06/2024
GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) [...]
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
03/06/2024
PRESS RELEASE BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage The seed round was co-led by UI Investissement (via the Pertinence Invest 2 Fund [...]
BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique
03/06/2024
COMMUNIQUÉ DE PRESSE BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique Ce tour de table a été réalisé par UI Investissement ( via le fonds Pertinence [...]

Pages